News

News Archive

April 16, 2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

July 18, 2023

U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure

June 26, 2023

Kaléo Expands Executive Team to Support Growth

April 4, 2023

Kaléo Welcomes Vice President, Marketing and Analytics Executive

December 12, 2022

Kaléo and Parexel Win Quality Award from the Abstract Committee of the American Conference on Pharmacometrics

October 25, 2022

Kaléo Announces Appointment of Major General Elder Granger, M.D., to Board 

September 27, 2022

Kaléo Adds Chief Business Officer to Executive Team

September 21, 2022

Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids

September 13, 2022

Rapid Opioid Countermeasure System Product Team Wins Award for Outstanding Program Management Team at 2022 Military Health System Research Symposium

August 11, 2022

Kaléo Announces Executive Appointments and New Government Business Unit 

August 2, 2022

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

May 8, 2022

Caring for the Caregiver

March 2, 2022

FDA Approves Kaléo’s Naloxone Auto-Injector 10 mg for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids

November 29, 2021

Marathon Asset Management Announces Acquisition of Kaléo

December 21, 2020

Kaléo Expands Executive Team with New Appointments

August 18, 2020

The Upcoming School Year is Expected to be Fraught with Uncertainty, Particularly for Children with Life-Threatening Food Allergies

August 10, 2020

Kaléo and the pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® (epinephrine injection, USP) Auto-Injector for the Treatment of Serious Allergic Reactions Across Canadian Provinces

August 10, 2020

Kaléo et l’Alliance pancanadienne pharmaceutique (APP) concluent leurs négociations sur l’auto-injecteur ALLERJECT® (épinéphrine injectable, USP) destiné au traitement des réactions allergiques graves dans les différentes provinces canadiennes.